{rfName}
Ad

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Nunez, OAuthor

Share

April 4, 2024
Publications
>
Article
Green

Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)

Publicated to: AMERICAN JOURNAL OF GASTROENTEROLOGY. 116 (6): 1220-1229 - 2021-06-01 116(6), DOI: 10.14309/ajg.0000000000001246

Authors:

Nyssen, OP; Perez-Aisa, A; Tepes, B; Castro-Fernandez, M; Kupcinskas, J; Jonaitis, L; Bujanda, L; Lucendo, A; Jurecic, NB; Perez-Lasala, J; Shvets, O; Fadeenko, G; Huguet, JM; Kikec, Z; Bordin, D; Voynovan, I; Leja, M; Machado, JC; Areia, M; Fernandez-Salazar, L; Rodrigo, L; Alekseenko, S; Barrio, J; Ortuño, J; Perona, M; Vologzhanina, L; Romero, PM; Zaytsev, O; Rokkas, T; Georgopoulos, S; Pellicano, R; Buzas, GM; Modolell, I; Rodriguez, BJG; Simsek, I; Simsek, C; Lafuente, MR; Ilchishina, T; Camarero, JG; Dominguez-Cajal, M; Ntouli, V; Dekhnich, NN; Phull, P; Nuñez, O; Lerang, F; Venerito, M; Heluwaert, F; Tonkic, A; Caldas, M; Puig, I; Megraud, F; O'Morain, C; Gisbert, JP
[+]

Affiliations

Aberdeen Royal Infirm Aberdeen, Gastroenterol Unit - Author
AI Yevdokimov Moscow State Univ Med & Dent, Dept Propaedeut Internal Dis & Gastroenterol, Gastroenterol Unit - Author
AM DC Rogaska, Gastroenterol Unit - Author
AS Loginov Moscow Clin Sci Ctr, Gastroenterol Unit - Author
Cent Hosp Ostfold, Med Dept, Gastroenterol Unit - Author
Consorci Hosp Gen Univ Valencia, Gastroenterol Unit - Author
Consorci Sanitari Terrassa, Gastroenterol Unit - Author
Ctr Hosp Annecy Genvois, Gastroenterol Unit - Author
Diagnost Ctr Bled, Gastroenterol Unit - Author
Digest Dis Ctr GASTRO, Gastroenterol Unit - Author
Dokuz Eylul Univ, Gastroenterol Unit, Sch Med - Author
Far Eastern State Med Univ Khabarovsk, Gastroenterol Unit - Author
Ferencvaros Policlin, Gastroenterol Unit - Author
First Clin Med Ctr Kovrov, Gastroenterol Unit - Author
Gastrocentr, Gastroenterol Unit - Author
Gen Hosp Pireaus, Gastroenterol Unit - Author
Hacettepe Univ Ankara, Gastroenterol Unit - Author
Henry Dunant Hosp, Gastroenterol Unit - Author
HM Sanchinarro, Gastroenterol Unit - Author
Hop Pellegrin, Lab Bacteriol, Gastroenterol Unit - Author
Hosp Clin Univ Valladolid, Gastroenterol Unit - Author
Hosp de Valme, Gastroenterol Unit - Author
Hosp Gen Univ Castellon, Gastroenterol Unit - Author
Hosp Quiron Marbella, Gastroenterol Unit - Author
Hosp Rio Hortega, Gastroenterol Unit - Author
Hosp San Jorge Huesca, Gastroenterol Unit - Author
Hosp San Pedro de Alcantara, Gastroenterol Unit - Author
Hosp Slovenj Gradec, Gastroenterol Unit - Author
Hosp Tomelloso, Gastroenterol Unit - Author
Hosp Univ & Politecn La Fe Valencia, Gastroenterol Unit - Author
Hosp Univ Burgos, Gastroenterol Unit - Author
Hosp Univ Cent Asturias, Gastroenterol Unit - Author
Hosp Univ Sanitas La Moraleja, Gastroenterol Unit - Author
Hosp Univ Virgen Macarena, Gastroenterol Unit - Author
Inst Antimicrobial Chemotherapy, Gastroenterol Unit - Author
Lithuanian Univ Hlth Sci, Gastroenterol Unit - Author
Molinette Hosp Turin, Gastroenterol Unit - Author
Natl Med Univ, Internal Dis Dept 1, Gastroenterol Unit - Author
Natl Ukrainian Acad Med Sci, Gastroenterol Unit - Author
Otto von Guericke Univ Hosp, Dept Gastroenterol Hepatol & Infect Dis, Gastroenterol Unit - Author
Paleo Faliron Gen Hosp Athens, Athens Med Ctr, Gastroenterol Unit - Author
Portuguese Oncol Inst Coimbra, Gastroenterol Unit - Author
Red Invest Serv Salud Enfermedades Cron REDISSEC, Marbella, Agencia Sanitaria Costa del Sol, Gastroenterol Unit - Author
SM Clin, Gastroenterol Unit - Author
Trinity Coll Dublin, Dept Clin Med, Gastroenterol Unit - Author
Univ Autonoma Madrid, Hosp Univ La Princesa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria Princesa IIS IP,Gastroenter - Author
Univ Pais Vasco UPV EHU, Hosp Donostia Inst Biodonostia, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Gastroenterol Unit - Author
Univ Porto, Ipatimup Inst Mol Pathol & Immunol - Author
Univ Split, Univ Hosp Split, Sch Med, Gastroenterol Unit - Author
Univ Vic, Univ Cent Catalunya UVicUCC - Author
See more

Abstract

INTRODUCTION: The safety of Helicobacter pylori eradication treatments and to what extent adverse events (AEs) influence therapeutic compliance in clinical practice are hardly known. Our aim was to assess the frequency, type, intensity, and duration of AEs, and their impact on compliance, for the most frequently used treatments in the European Registry on Helicobacter pylori management. METHODS: Systematic prospective non interventional registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H. pylori infection in routine clinical practice. All prescribed eradication treatments and their corresponding safety profile were recorded. AEs were classified depending on the intensity of symptoms as mild/moderate/severe and as serious AEs. All data were subject to quality control. RESULTS: The different treatments prescribed to 22,492 patients caused at least 1 AE in 23% of the cases; the classic bismuth-based quadruple therapy was the worst tolerated (37% of AEs). Taste disturbance (7 %) , diarrhea (7 %) , nausea (6%), and abdominal pain (3%) were the most frequent AEs. The majority of AEs were mild (57%), 6% were severe, and only 0.08% were serious, with an average duration of 7 days. The treatment compliance rate was 97%. Only 1.3% of the patients discontinued treatment due to AEs. Longer treatment durations were significantly associated with a higher incidence of AEs in standard triple, concomitant, bismuth quadruple, and levofloxacin triple or quadruple therapies. DISCUSSION: Helicobacter pylori eradication treatment frequently induces AEs, although they are usually mild and of limited duration. Their appearance does not interfere significantly with treatment compliance.
[+]

Keywords

Abdominal painAdultAdverse drug reactionAmoxicillinAnti-bacterial agentsAntiinfective agentArticleBismuthClarithromycinClinical trialCombination drug therapyDiarrheaDoxycyclineDrug effectDrug safetyDrug therapy, combinationDrug-related side effects and adverse reactionsEradication therapyEuropeFemaleHelicobacter infectionHelicobacter infectionsHelicobacter pyloriHumanHumansIncidenceJosamycinLevofloxacinMajor clinical studyMaleMetallic tasteMetronidazoleMiddle agedMulticenter studyNauseaPeptic ulcerProton pump inhibitorProton pump inhibitorsQuality controlRegisterRegistriesTetracyclineTreatment outcomeTreatment planning

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal AMERICAN JOURNAL OF GASTROENTEROLOGY due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 9/93, thus managing to position itself as a Q1 (Primer Cuartil), in the category Gastroenterology & Hepatology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 4.03. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 5.5 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-09, the following number of citations:

  • WoS: 62
  • Scopus: 72
  • Europe PMC: 28
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-09:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 48.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 48 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 16.
  • The number of mentions on the social network X (formerly Twitter): 7 (Altmetric).
  • The number of mentions in news outlets: 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: China; Croatia; France; Germany; Greece; Hungary; Italy; Latvia; Lithuania; Norway; Portugal; Russia; Slovenia; Turkey; Ukraine; United Kingdom.

[+]